Travoprost
drugOn this page
Also known as AL-6221Idose trIzbaNSC-760366Otx-tpTravatanTravatan zTravoprost component of duotrav
Summary
Travoprost (CHEMBL1200799) is an approved small-molecule antiglaucoma drug (ATC S01EE04); indicated across 4 conditions including open-angle glaucoma and ocular hypertension.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: S01EE04
- Indications: 4 conditions
- Clinical trials: 96
- Chemistry: 500.5 Da · C26H35F3O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200799 |
| Name | Travoprost |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5282226 |
| ChEBI | CHEBI:746859 |
| ATC | S01EE04 |
| Molecular formula | C26H35F3O6 |
| Molecular weight | 500.5 |
| InChIKey | MKPLKVHSHYCHOC-AHTXBMBWSA-N |
SMILES: CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O
IUPAC name: propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
ChEBI definition: The isopropyl ester of prostaglandin F2α in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2α, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.
Pharmacological roles (ChEBI): antiglaucoma drug, antihypertensive agent, prodrug, ophthalmology drug, prostaglandin receptor agonist.
Also known as: AL-6221, Idose tr, Izba, NSC-760366, Otx-tp, Travatan, Travatan z, Travoprost, Travoprost component of duotrav, TRAVOPROST, travoprost
Patent coverage: 2,143 distinct patent families (9,398 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 9,393 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, Bile salt export pump.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| open-angle glaucoma | 4 | MONDO:0005338 | EFO:0004190 |
| ocular hypertension | 4 | MONDO:0006875 | EFO:1001069 |
| glaucoma | 4 | MONDO:0005041 | MONDO:0005041 |
| exfoliation syndrome | 3 | MONDO:0008327 | EFO:0004235 |
Clinical trials
Total trials: 96.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 48 |
| PHASE3 | 25 |
| Not specified | 13 |
| PHASE2 | 9 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00061503 | PHASE4 | COMPLETED | Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension |
| NCT00308945 | PHASE4 | COMPLETED | Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients |
| NCT00329095 | PHASE4 | COMPLETED | An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance |
| NCT00440011 | PHASE4 | COMPLETED | Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005% |
| NCT00444184 | PHASE4 | COMPLETED | 24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost |
| NCT00471068 | PHASE4 | TERMINATED | Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension |
| NCT00471380 | PHASE4 | COMPLETED | A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension |
| NCT00508469 | PHASE4 | COMPLETED | Adherence Assessment With Travalert Dosing Aid |
| NCT00519753 | PHASE4 | COMPLETED | Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav |
| NCT00539526 | PHASE4 | COMPLETED | Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues |
| NCT00705757 | PHASE4 | COMPLETED | The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye |
| NCT00758342 | PHASE4 | TERMINATED | Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG) |
| NCT00759239 | PHASE4 | COMPLETED | Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension |
| NCT00762645 | PHASE4 | COMPLETED | Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG) |
| NCT00763061 | PHASE4 | COMPLETED | Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension |
| NCT00798694 | PHASE4 | COMPLETED | How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used? |
| NCT00799682 | PHASE4 | COMPLETED | Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® |
| NCT00847483 | PHASE4 | COMPLETED | Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US |
| NCT00966940 | PHASE4 | COMPLETED | Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension |
| NCT01230736 | PHASE4 | COMPLETED | Safety and Efficacy of Changing to DuoTrav From Prior Therapy |
| NCT01315574 | PHASE4 | TERMINATED | Effects of Anti-Glaucoma Medications on the Ocular Surface |
| NCT01327599 | PHASE4 | COMPLETED | Efficacy of Changing to DUOTRAV® From Prior Therapy |
| NCT01336569 | PHASE4 | COMPLETED | Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol |
| NCT01443988 | PHASE4 | COMPLETED | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost |
| NCT01444040 | PHASE4 | COMPLETED | Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost |
| NCT01464424 | PHASE4 | COMPLETED | Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) |
| NCT01493427 | PHASE4 | COMPLETED | Efficacy of Changing to TRAVATAN® From Prior Therapy |
| NCT01510132 | PHASE4 | WITHDRAWN | Travacom Post Marketing Surveillance Study |
| NCT01510145 | PHASE4 | COMPLETED | Efficacy of Changing to TRAVATAN® From Prior Therapy |
| NCT01514721 | PHASE4 | TERMINATED | Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy |
| NCT01547598 | PHASE4 | COMPLETED | Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction |
| NCT01655758 | PHASE4 | COMPLETED | 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension |
| NCT01664039 | PHASE4 | COMPLETED | An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN® |
| NCT01696383 | PHASE4 | WITHDRAWN | Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia |
| NCT01779284 | PHASE4 | COMPLETED | Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy |
| NCT01881126 | PHASE4 | COMPLETED | An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension |
| NCT01937299 | PHASE4 | COMPLETED | Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® |
| NCT01978015 | PHASE4 | COMPLETED | Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG |
| NCT02003391 | PHASE4 | COMPLETED | Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure |
| NCT02097719 | PHASE4 | COMPLETED | Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).